Jérôme Nicol
Biographic Data
| ID | 8760733 |
|---|---|
| NAME | Jérôme Nicol |
| GIVEN NAMES | Jérôme |
| FAMILY NAME | Nicol |
| SIGNATURE | NICOL J |
| AFFILIATIONS | Sorbonne Université, Inserm, Institut Pierre-Louis d’Epidémiologie et de Santé Publique, Paris, France |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Hepatitis C virus cure from direct‐acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? ( ANRS CO22 Hepather cohort)
Impaired health-related quality of life in the HCV cure era: Who is concerned? (ANRS CO22 Hepather French cohort)
Antibody status and cumulative incidence of Sars-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: A multicohort study
BACKGROUND: We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors. METHODS: Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with …
No prominent works on this page.
Antibody status and cumulative incidence of Sars-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: A multicohort study
BACKGROUND: We aimed to estimate the seropositivity to anti-SARS-CoV-2 antibodies in May-June 2020 after the first lockdown period in adults living in three regions in France and to identify the associated risk factors. METHODS: Between 4 May 2020 and 23 June 2020, 16 000 participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) (two regions with …
Impaired health-related quality of life in the HCV cure era: Who is concerned? (ANRS CO22 Hepather French cohort)
Hepatitis C virus cure from direct‐acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? ( ANRS CO22 Hepather cohort)
Cohort (3 works) · Internal Medicine (3 works) · Medicine (3 works) · Cohort study (2 works) · Environmental health (2 works) · Hepatitis C (2 works) · Hepatitis C virus research (2 works) · Population (2 works) · 2019-20 coronavirus outbreak (1 works) · Antibody (1 works)